Chiesi USA

Chiesi USA, part of the global Chiesi Group based in Parma, Italy, operates from its headquarters in Cary, North Carolina. The company specializes in developing and providing a range of pharmaceutical products aimed at treating respiratory diseases, neonatology issues, and special care needs. Its product portfolio includes BETHKIS (Tobramycin Inhalation Solution), BRONCHITOL (mannitol) inhalation powder, CLEVIPREX (clevidipine) injectable emulsion, CUROSURF (poractant alfa) Intratracheal Suspension, KENGREAL (cangrelor) for injection, and RETAVASE (reteplase) for injection. These products cater to acute, rare, and chronic disorders, primarily in hospital, rare diseases, and adjacent specialty care settings. In 2022, Chiesi USA reported revenues exceeding $478 million. As a Public Benefit Corporation and Certified B Corporation, Chiesi USA is committed to sustainability and social responsibility, actively engaging in community health initiatives and supporting medical education through its grant program. The company maintains a comprehensive compliance program that aligns with industry standards and regulations, ensuring adherence to legal and ethical standards. Chiesi USA also supports patients through financial assistance and copay programs, reflecting its commitment to patient care. Globally, Chiesi has a presence in over 100 countries, including Austria, Belgium, Brazil, and many others, enhancing its reach and impact in the pharmaceutical industry.